21.16
2.47%
0.51
Genmab Adr Stock (GMAB) Forecast
The Genmab Adr (GMAB) stock price forecast for the next 30 days is generally positive, with an average analyst price target of $34.68, representing a +63.88% increase from the current price of $21.16. The highest analyst price target is $35.76, and the lowest is $33.59.
Disclaimer: The information on this page is not intended to be financial advice. It is for general information only and should not be used to make any investment decisions. Please consult with a professional financial advisor before making any investment decisions.
12-Month GMAB Price Target
Average 40.06
(+89.30% Upside)
Is Genmab Adr (GMAB) A Buy Now?
Oscillators
Name | Value | Action |
---|---|---|
RSI(14) | 40.05 | Neutral |
STOCH(9,6) | 27.15 | Neutral |
STOCHRSI(14) | 62.74 | Neutral |
MACD(12,26) | -0.7065 | Buy |
ADX(14) | 41.74 | Sell |
William %R | -73.80 | Neutral |
CCI(14) | -19.53 | Neutral |
Buy: 1
Sell: 1
Neutral: 5
Summary: Neutral
Moving Averages
Period | Simple | Exponential |
---|---|---|
MA10 |
20.71
Buy
|
21.00
Buy
|
MA20 |
21.67
Sell
|
21.51
Sell
|
MA50 |
22.83
Sell
|
22.85
Sell
|
MA100 |
25.04
Sell
|
24.38
Sell
|
MA200 |
26.78
Sell
|
26.62
Sell
|
Buy: 2
Sell: 8
Neutral: 0
Summary: Sell
According to our latest analysis, GMAB could be considered a Strong Sell, with 17 technical analysis indicators signaling 3 Buy signals, 9 signaling Sell signals and 5 Neutral signals. This might not be a good time to consider opening new positions on GMAB, as trading bearish markets can be challenging and may result in losses.
- RSI (Relative Strength Index): The RSI(14) value of 40.05 indicates that GMAB is neither overbought nor oversold. It suggests a neutral sentiment in the short term.
- STOCH (Stochastic Oscillator): The STOCH value of 27.15 indicates that GMAB is neither overbought nor oversold. It indicates a balanced market sentiment without any extreme buying or selling pressure.
- STOCHRSI (Stochastic Relative Strength Index): The STOCHRSI value of 62.74 indicates that GMAB is neither overbought nor oversold. It indicates a balanced market sentiment without any extreme buying or selling pressure.
- ADX (Average Directional Index): The ADX value of The ADX value of 41.74 suggests a moderate trend in the market. It indicates that there is more conviction behind the directional movement compared to lower ADX values. You should consider this as a potential opportunity to enter trades in the direction of the trend.
- CCI (Commodity Channel Index): A CCI(14) value of A CCI(14) value of -19.53 indicates that GMAB is not in oversold or overbought territory. It suggests a neutral sentiment in the short term.
Long-term GMAB price forecast for 2025, 2030, 2035, 2040, 2045 and 2050
Based on our analysis about Genmab Adr financial reports and earnings history, Genmab Adr (GMAB) stock could reach $43.21 by 2030, $84.80 by 2040 and $120.26 by 2050. See the projected annual prices until 2050 of the Genmab Adr stock below:
- Genmab Adr (GMAB) is expected to reach an average price of $63.75 in 2035, with a high prediction of $65.66 and a low estimate of $61.16. This indicates an $201.27% rise from the last recorded price of $21.16.
- Genmab Adr (GMAB) stock is projected to chart a bullish course in 2040, with an average price target of $77.53, representing an $266.38% surge from its current level. The forecast ranges from a conservative $77.04 to a sky-high $84.80.
- Our analysts predict Genmab Adr (GMAB) to jump 381.98% by 2045, soaring from $101.96 to an average price of $101.99, potentially reaching $105.57. While $101.96 is the low estimate, the potential upside is significant.
- Genmab Adr (GMAB) stock is expected to climb by 2050, reaching an average of $117.11, a $453.43% jump from its current level. However, a wide range of estimates exists, with high and low targets of $120.26 and $115.90, respectively, highlighting the market's uncertainty.
Genmab Adr Stock (GMAB) Year by Year Forecast
Genmab Adr Stock (GMAB) Price Forecast for 2024
Our forecast for GMAB stock price in 2024 now indicates an average price target of $31.04 with a high forecast of $35.76 and a low forecast of $26.32. The average prediction reflects an increase of +46.69% from the last recorded price of $21.16.
Month | Average | Low | High | Change from today's price |
---|---|---|---|---|
December, 2024 | $35.71 | $33.59 | $35.76 | +68.76% |
Genmab Adr Stock (GMAB) Price Forecast for 2025
Genmab Adr Stock (GMAB) is expected to reach an average price of $41.00 in 2025, with a high prediction of $54.15 and a low estimate of $27.86. This indicates an +93.77% rise from the last recorded price of $21.16.
Month | Average | Low | High | Change from today's price |
---|---|---|---|---|
January, 2025 | $30.52 | $29.29 | $36.93 | +44.25% |
February, 2025 | $31.73 | $27.86 | $33.28 | +49.96% |
March, 2025 | $36.08 | $32.63 | $36.35 | +70.52% |
April, 2025 | $42.29 | $35.93 | $43.16 | +99.88% |
May, 2025 | $43.95 | $39.84 | $45.48 | +107.72% |
June, 2025 | $47.93 | $44.45 | $48.21 | +126.53% |
July, 2025 | $50.39 | $46.00 | $50.45 | +138.12% |
August, 2025 | $47.79 | $46.23 | $50.79 | +125.83% |
September, 2025 | $49.56 | $46.70 | $51.14 | +134.20% |
October, 2025 | $52.08 | $45.72 | $52.26 | +146.12% |
November, 2025 | $51.16 | $47.30 | $51.20 | +141.77% |
December, 2025 | $53.32 | $50.47 | $54.15 | +151.99% |
Genmab Adr Stock (GMAB) Price Forecast for 2026
The predicted value for Genmab Adr (GMAB) in 2026 is set at an average of $52.76. Estimates vary from a peak of $62.57 to a trough of $42.95, indicating an +149.35% surge from the present price of $21.16.
Month | Average | Low | High | Change from today's price |
---|---|---|---|---|
January, 2026 | $52.42 | $52.35 | $57.52 | +147.73% |
February, 2026 | $46.70 | $46.16 | $54.76 | +120.70% |
March, 2026 | $45.93 | $42.95 | $48.09 | +117.06% |
April, 2026 | $49.84 | $44.46 | $50.29 | +135.55% |
May, 2026 | $52.37 | $48.53 | $52.60 | +147.50% |
June, 2026 | $56.13 | $52.53 | $58.13 | +165.27% |
July, 2026 | $56.54 | $53.90 | $57.77 | +167.22% |
August, 2026 | $59.98 | $56.11 | $61.03 | +183.47% |
September, 2026 | $57.51 | $57.47 | $62.57 | +171.76% |
October, 2026 | $56.80 | $55.54 | $58.61 | +168.41% |
November, 2026 | $58.34 | $55.64 | $60.56 | +175.73% |
December, 2026 | $52.34 | $51.62 | $61.01 | +147.34% |
Genmab Adr Stock (GMAB) Price Forecast for 2027
For 2027, Stockscan's Analyst expects the average price target for Genmab Adr (GMAB) is $47.47, with a high forecast of $54.19 and a low forecast of $40.75. This indicates an +124.34% increase from the last price of $21.16.
Month | Average | Low | High | Change from today's price |
---|---|---|---|---|
January, 2027 | $53.60 | $49.69 | $54.19 | +153.29% |
February, 2027 | $47.50 | $47.35 | $54.18 | +124.46% |
March, 2027 | $46.31 | $45.62 | $49.47 | +118.85% |
April, 2027 | $45.91 | $44.21 | $48.84 | +116.96% |
May, 2027 | $50.93 | $46.55 | $51.95 | +140.68% |
June, 2027 | $45.21 | $45.06 | $53.01 | +113.66% |
July, 2027 | $44.74 | $41.84 | $45.60 | +111.44% |
August, 2027 | $46.89 | $40.75 | $46.92 | +121.60% |
September, 2027 | $50.37 | $45.63 | $50.99 | +138.05% |
October, 2027 | $50.67 | $49.12 | $52.93 | +139.47% |
November, 2027 | $52.31 | $49.15 | $52.55 | +147.22% |
December, 2027 | $51.48 | $46.34 | $52.53 | +143.31% |
Genmab Adr Stock (GMAB) Price Forecast for 2028
In 2028, Genmab Adr (GMAB) is projected to reach an average price of $56.40, with a high projection of $62.69 and a low estimate of $50.12. This indicates an +166.55% rise from the last price of $21.16.
Month | Average | Low | High | Change from today's price |
---|---|---|---|---|
January, 2028 | $55.02 | $50.12 | $55.02 | +160.04% |
February, 2028 | $61.69 | $54.20 | $61.73 | +191.56% |
March, 2028 | $57.66 | $57.07 | $62.69 | +172.48% |
April, 2028 | $54.24 | $53.81 | $58.98 | +156.31% |
May, 2028 | $52.91 | $52.36 | $55.57 | +150.04% |
June, 2028 | $51.42 | $50.20 | $53.83 | +142.99% |
July, 2028 | $57.24 | $51.39 | $57.30 | +170.50% |
August, 2028 | $57.41 | $55.17 | $58.67 | +171.31% |
September, 2028 | $54.41 | $54.38 | $58.20 | +157.13% |
October, 2028 | $53.63 | $52.74 | $55.41 | +153.45% |
November, 2028 | $53.47 | $53.38 | $58.74 | +152.70% |
December, 2028 | $54.44 | $51.85 | $55.68 | +157.28% |
Genmab Adr Stock (GMAB) Price Forecast for 2029
The 2029 price forecast for Genmab Adr Stock (GMAB) is $47.09 on average, with a high prediction of $55.02 and a low estimate of $39.16. This represents an +122.54% increase from the previous price of $21.16.
Month | Average | Low | High | Change from today's price |
---|---|---|---|---|
January, 2029 | $51.53 | $51.43 | $55.02 | +143.54% |
February, 2029 | $44.77 | $44.38 | $52.19 | +111.59% |
March, 2029 | $49.24 | $44.14 | $49.33 | +132.72% |
April, 2029 | $48.81 | $46.69 | $49.35 | +130.68% |
May, 2029 | $48.25 | $46.39 | $49.52 | +128.05% |
June, 2029 | $44.53 | $44.00 | $46.67 | +110.47% |
July, 2029 | $44.59 | $43.10 | $46.28 | +110.75% |
August, 2029 | $46.85 | $45.26 | $48.77 | +121.39% |
September, 2029 | $45.18 | $44.46 | $47.46 | +113.50% |
October, 2029 | $39.82 | $39.16 | $46.07 | +88.18% |
November, 2029 | $41.81 | $39.53 | $42.68 | +97.59% |
December, 2029 | $42.37 | $41.18 | $43.19 | +100.23% |
Genmab Adr Stock (GMAB) Price Forecast for 2030
Genmab Adr Stock (GMAB) is expected to reach an average price of $50.14 in 2030, with a high forecast of $60.82 and a low forecast of $39.45. This signifies an +136.94% surge from the last price of $21.16.
Month | Average | Low | High | Change from today's price |
---|---|---|---|---|
January, 2030 | $43.15 | $40.97 | $43.21 | +103.94% |
February, 2030 | $44.31 | $42.76 | $44.48 | +109.42% |
March, 2030 | $46.29 | $44.12 | $46.93 | +118.77% |
April, 2030 | $44.94 | $44.16 | $46.18 | +112.39% |
May, 2030 | $46.00 | $43.92 | $46.20 | +117.37% |
June, 2030 | $45.55 | $45.29 | $48.43 | +115.25% |
July, 2030 | $44.60 | $39.45 | $47.27 | +110.75% |
August, 2030 | $46.24 | $42.95 | $46.60 | +118.52% |
September, 2030 | $52.31 | $47.34 | $52.77 | +147.21% |
October, 2030 | $55.52 | $51.75 | $55.97 | +162.38% |
November, 2030 | $58.96 | $55.76 | $59.81 | +178.65% |
December, 2030 | $60.74 | $58.09 | $60.82 | +187.06% |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):